{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:34:40Z","timestamp":1793385280441,"version":"4.5.0"},"reference-count":81,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Uterine sarcoma (US) is a rare mesenchymal malignant cancer type, accounting for 3\u20137% of uterine malignancies. US prognosis is still poor due to high local and distant recurrence rates. As for molecular features, US may present variable oestrogen receptor (ER) and progesterone receptor (PR) expressions, mostly depending on histotype and grading. Surgery represents the mainstay of treatment for early-stage disease, while the role of adjuvant chemotherapy or local radiotherapy is still debated and defined on the basis of histotype, tumour grading and stage. In metastatic setting, uterine sarcomas\u2019 treatment includes palliative surgery, a metastases resection, chemotherapy, hormonal therapy and targeted therapy. As for the chemotherapy regimen used, drugs that are considered most effective are doxorubicin (combined with ifosfamide or alone), gemcitabine combined with docetaxel and, more recently, trabectedin or pazopanib. Hormonal therapies, including aromatase inhibitors (AIs), progestins and gonadotropin-releasing hormone analogues (GnRH-a) may also represent an effective option, in particular for low-grade endometrial stromal sarcoma (LGESS), due to their favourable toxicity profile and patients\u2019 compliance, while their role is still under investigation in uterine leiomyosarcoma (uLMS), high-grade endometrial stromal sarcoma (HGESS), undifferentiated uterine sarcoma (USS) and other rarer US. The present review aims to analyse the existing evidence and future perspectives on hormonal therapies in US, in order to clarify their potential role in daily clinical practice.<\/jats:p>","DOI":"10.3390\/cancers14040921","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:32:30Z","timestamp":1644784350000},"page":"921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["New Insights into Hormonal Therapies in Uterine Sarcomas"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3212-4246","authenticated-orcid":false,"given":"Elena","family":"Maccaroni","sequence":"first","affiliation":[{"name":"Department of Oncology, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Lunerti","sequence":"additional","affiliation":[{"name":"Department of Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-1528","authenticated-orcid":false,"given":"Veronica","family":"Agostinelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Universit\u00e0 Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zepponi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pagliacci","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Universit\u00e0 Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tjog.2016.04.033","article-title":"Uterine Sarcoma Part I\u2014Uterine Leiomyosarcoma: The Topic Advisory Group Systematic Review","volume":"55","author":"Wen","year":"2016","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ajcp\/aqw030","article-title":"Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma","volume":"145","author":"Davidson","year":"2016","journal-title":"Am. J. Clin. Pathol"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00000478-199005000-00002","article-title":"Primary Uterine Endometrial Stromal Neoplasms. A Clinicopathologic Study of 117 Cases","volume":"14","author":"Chang","year":"1990","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3857\/roj.2015.33.1.29","article-title":"Outcome Analysis in Patients with Uterine Sarcoma","volume":"33","author":"Yu","year":"2015","journal-title":"Radiat. Oncol. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ijgo.2015.06.006","article-title":"Uterine Sarcomas","volume":"131","author":"Prat","year":"2015","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO Staging for Uterine Sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2020.08.016","article-title":"Italian Consensus Conference on Management of Uterine Sarcomas on Behalf of S.I.G.O. (Societa\u2019 Italiana Di Ginecologia E Ostetricia)","volume":"139","author":"Ferrandina","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/0284186X.2012.689111","article-title":"Diagnosis and Treatment of Sarcoma of the Uterus. A Review","volume":"51","author":"Abeler","year":"2012","journal-title":"Acta Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine Sarcomas: A Review","volume":"116","author":"Prat","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/jog.14436","article-title":"Endometrial Stromal Sarcoma: A Review of Rare Mesenchymal Uterine Neoplasm","volume":"46","author":"Capozzi","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2007.01.031","article-title":"A Multi-Institutional Review of Outcomes of Endometrial Stromal Sarcoma","volume":"105","author":"Leath","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.05.036","article-title":"Low-Grade and High-Grade Endometrial Stromal Sarcoma: A National Cancer Database Study","volume":"146","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/AOG.0b013e3182a189ac","article-title":"Endometrial Stromal Sarcoma: A Systematic Review","volume":"122","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/IGC.0000000000000842","article-title":"Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis","volume":"27","author":"Si","year":"2017","journal-title":"Int. J. Gynecol Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.18632\/oncotarget.12491","article-title":"Fertility-Sparing Surgery for Patients with Low-Grade Endometrial Stromal Sarcoma","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/01.AOG.0000185511.91694.1e","article-title":"Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas","volume":"106","author":"Li","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2010.12.360","article-title":"Recurrence Patterns and Prognosis of Endometrial Stromal Sarcoma and the Potential of Tyrosine Kinase-Inhibiting Therapy","volume":"121","author":"Cheng","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical Management of Uterine Sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1586\/era.12.74","article-title":"Hormonal Therapy in Gynecological Sarcomas","volume":"12","author":"Thanopoulou","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_21","first-page":"1755","article-title":"Progestin Therapy for Endometrial Cancer: The Potential of Fourth-Generation Progestin (Review)","volume":"40","author":"Banno","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cam4.2044","article-title":"Hormonal Therapy in Uterine Sarcomas","volume":"8","author":"Zang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cncr.24197","article-title":"Phase 2 Trial of Mifepristone (RU-486) in Advanced or Recurrent Endometrioid Adenocarcinoma or Low-Grade Endometrial Stromal Sarcoma","volume":"115","author":"Ramondetta","year":"2009","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1933719118778801","article-title":"Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma","volume":"26","author":"Deshmukh","year":"2019","journal-title":"Reprod. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0090-8258(87)90074-6","article-title":"Endometrial Stromal Sarcoma: A Clinicopathologic Study of 11 Cases with Determination of Estrogen and Progestin Receptor Levels in Three Tumors","volume":"26","author":"Katz","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0090-8258(03)00258-0","article-title":"Low-Grade Endometrial Stromal Sarcoma: Hormonal Aspects","volume":"90","author":"Chu","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2011.10.010","article-title":"Endometrial Stromal Sarcoma: Analysis of Recurrence Following Adjuvant Treatment","volume":"125","author":"Beck","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/annonc\/mdq064","article-title":"Impact of Adjuvant Treatment Modalities on the Management of Patients with Stages I\u2013II Endometrial Stromal Sarcoma","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2009.08.014","article-title":"Hormone Receptor Expression in Uterine Sarcomas: Prognostic and Therapeutic Roles","volume":"115","author":"Ioffe","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or Benefit of Hormonal Treatment in Metastatic Low-Grade Endometrial Stromal Sarcoma: Single Center Experience with 10 Cases and Review of the Literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejogrb.2009.02.005","article-title":"The Efficacy of Hormonal Treatment for Residual or Recurrent Low-Grade Endometrial Stromal Sarcoma. A Retrospective Study","volume":"144","author":"Dahhan","year":"2009","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3802\/jgo.2015.26.3.214","article-title":"Long-Term Survival of Patients with Recurrent Endometrial Stromal Sarcoma: A Multicenter, Observational Study","volume":"26","author":"Yamazaki","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s10147-011-0299-y","article-title":"Long-Term Medroxyprogesterone Acetate Therapy for Low-Grade Endometrial Stromal Sarcoma","volume":"17","author":"Mizuno","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100634","DOI":"10.1016\/j.gore.2020.100634","article-title":"Potential Alternative Progestin Therapy for Low-Grade Endometrial Stromal Sarcoma: A Case Report","volume":"34","author":"Maenohara","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2014.04.060","article-title":"The Therapeutic Significance of Aromatase Inhibitors in Endometrial Carcinoma","volume":"134","author":"Gao","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/modpathol.3800031","article-title":"Aromatase Expression in Low-Grade Endometrial Stromal Sarcomas: An Immunohistochemical Study","volume":"17","author":"Reich","year":"2004","journal-title":"Mod. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/CCO.0b013e3281a7ef3a","article-title":"Hormonal Therapy of Endometrial Stromal Sarcoma","volume":"19","author":"Reich","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13256-021-02838-x","article-title":"Complete Remission of Advanced Low-Grade Endometrial Stromal Sarcoma after Aromatase Inhibitor Therapy: A Case Report","volume":"15","author":"Altal","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MO:20:1:87","article-title":"Long-Term Survival of Patients Given Hormonal Therapy for Metastatic Endometrial Stromal Sarcoma","volume":"20","author":"Spano","year":"2003","journal-title":"Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ygyno.2004.07.063","article-title":"Low-Grade Endometrial Stromal Sarcoma Treated with the Aromatase Inhibitor Letrozole","volume":"95","author":"Leunen","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00404-008-0631-6","article-title":"Long-Term Disease-Free Survival after Hormonal Therapy of a Patient with Recurrent Low Grade Endometrial Stromal Sarcoma: A Case Report","volume":"279","author":"Alkasi","year":"2009","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.3892\/ol.2015.3674","article-title":"Long-Term Treatment of Residual or Recurrent Low-Grade Endometrial Stromal Sarcoma with Aromatase Inhibitors: A Report of Two Cases and a Review of the Literature","volume":"10","author":"Ryu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/IGC.0000000000000557","article-title":"Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma","volume":"25","author":"Yamaguchi","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2021.02.016","article-title":"Phase 2 study of anastrozole in patients with estrogen receptor\/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)","volume":"161","author":"Friedlander","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/gyno.2001.6238","article-title":"Endometrial Stromal Sarcoma: Objective Response to Letrozole","volume":"82","author":"Maluf","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.6004\/jnccn.2021.0038","article-title":"NCCN Guidelines\u00ae Insights: Uterine Neoplasms, Version 3. 2021","volume":"19","author":"Yashar","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/modpathol.3800325","article-title":"Gonadotropin-Releasing Hormone Receptor Expression in Endometrial Stromal Sarcomas: An Immunohistochemical Study","volume":"18","author":"Reich","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.path.2019.01.004","article-title":"Uterine Mesenchymal Tumors","volume":"12","author":"Howitt","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1067\/mob.2000.103939","article-title":"Effects of Leuprolide Acetate on Low-Grade Endometrial Stromal Sarcoma","volume":"182","author":"Mesia","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.AOG.0000133533.05148.aa","article-title":"Treatment of Endometrial Stromal Sarcoma With a Gonadotropin-Releasing Hormone Analogue","volume":"104","author":"Burke","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1006\/gyno.1998.5174","article-title":"Low-Grade Endometrial Stromal Sarcoma Preoperative Treatment with Depo-Lupron and Megace","volume":"71","author":"Scribner","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJM200206063462319","article-title":"Uterine Sarcoma Associated with Tamoxifen Use","volume":"346","author":"Wysowski","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41379-020-00705-6","article-title":"Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma","volume":"34","author":"Mohammad","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijgo.2013.01.025","article-title":"Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy","volume":"122","author":"Malouf","year":"2013","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine Leiomyosarcoma: Epidemiology, Contemporary Treatment Strategies and the Impact of Uterine Morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_56","unstructured":"(2022, February 11). Linee Guida AIOM 2020\u2014Sarcomi Dei Tessuti Molli e Gist. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-2020-sarcomi-dei-tessuti-molli-e-gist\/."},{"key":"ref_57","unstructured":"NCCN (2022, February 11). Clinical Practice Guidelines in Oncology\u2014Version 1.2022. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1473."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.20521","article-title":"Tissue Microarray Immunohistochemical Expression of Estrogen, Progesterone, and Androgen Receptors in Uterine Leiomyomata and Leiomyosarcoma","volume":"101","author":"Leitao","year":"2004","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2005.05.019","article-title":"The Expression of Ki-67, P53, Estrogen and Progesterone Receptors Affecting Survival in Uterine Leiomyosarcomas","volume":"99","author":"Akhan","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2011.11.009","article-title":"Immunohistochemical Expression of Estrogen and Progesterone Receptors and Outcomes in Patients with Newly Diagnosed Uterine Leiomyosarcoma","volume":"124","author":"Leitao","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13277-010-0138-1","article-title":"Immunohistochemical Studies on Uterine Carcinosarcoma, Leiomyosarcoma, and Endometrial Stromal Sarcoma: Expression and Prognostic Importance of Ten Different Markers","volume":"32","author":"Butzow","year":"2011","journal-title":"Tumour Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-4-5","article-title":"Treatment of Hormone Positive Uterine Leiomyosarcoma with Aromatase Inhibitors","volume":"4","author":"Thanopoulou","year":"2014","journal-title":"Clin. Sarcoma Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0301-2115(02)00147-1","article-title":"Neoadjuvant Therapy of Endometrial Cancer with the Aromatase Inhibitor Letrozole: Endocrine and Clinical Effects","volume":"105","author":"Berstein","year":"2002","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_64","first-page":"2233","article-title":"CA125 Response Is Associated with Estrogen Receptor Expression in a Phase II Trial of Letrozole in Ovarian Cancer: Identification of an Endocrine-Sensitive Subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.AOG.0000267533.56546.c2","article-title":"Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor","volume":"110","author":"Hardman","year":"2007","journal-title":"Obs. Gynecol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gore.2018.11.001","article-title":"A Randomized Phase II Study of Letrozole vs. Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma (ULMS)","volume":"27","author":"Slomovitz","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsbmb.2003.11.013","article-title":"Aromatase Cytochrome P450 and Estrogen and Progesterone Receptors in Uterine Sarcomas: Correlation with Clinical Parameters","volume":"88","author":"Kitaoka","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of Advanced Uterine Leiomyosarcoma with Aromatase Inhibitors","volume":"116","author":"Zhou","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2019.08.007","article-title":"Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis","volume":"143","author":"Pannier","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_71","first-page":"379","article-title":"Hormone Replacement Therapy after Uterine Leiomyosarcoma Treatment. Case Reports","volume":"20","year":"1999","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","article-title":"Association of Tamoxifen and Uterine Sarcoma","volume":"20","author":"Wickerham","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<79::AID-CNCR13>3.0.CO;2-4","article-title":"Aggressive Angiomyxoma: A Clinicopathologic Study of 29 Female Patients","volume":"78","author":"Fetsch","year":"1996","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E226973","DOI":"10.1136\/bcr-2018-226973","article-title":"Aggressive Angiomyxoma: Giant Recurrence Successfully Treated with Wide Excision and Adjuvant Therapy with GnRH Analogue","volume":"11","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1634\/theoncologist.2018-0338","article-title":"Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study","volume":"24","author":"Hindi","year":"2019","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/IGC.0b013e31825b7de8","article-title":"Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature","volume":"22","author":"Altman","year":"2012","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.3802\/jgo.2018.29.e30","article-title":"Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma","volume":"29","author":"Baek","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/PAS.0000000000001215","article-title":"Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas","volume":"43","author":"Cotzia","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_80","first-page":"133","article-title":"Recent advances in the treatment of sarcomas in gynecology","volume":"18","author":"Lange","year":"2014","journal-title":"Discov. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"EORTC Soft Tissue and Bone Sarcoma Group; PALETTE Study Group. Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:30Z","timestamp":1760134710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040921"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040921","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]}}}